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Survival and Cardiac Remodeling Benefits
in Patients Undergoing Late Percutaneous
Coronary Intervention of the Infarct-Related Artery
Evidence From a Meta-Analysis of Randomized Controlled Trials
Antonio Abbate, MD,* Giuseppe G. L. Biondi-Zoccai, MD,† Darryn L. Appleton, MBCHB,*
Paul Erne, MD,‡ Andreas W. Schoenenberger, MD,§ Michael J. Lipinski, MD,
Pierfrancesco Agostoni, MD,¶ Imad Sheiban, MD,† George W. Vetrovec, MD, FACC*
Richmond and Charlottesville, Virginia; Turin, Italy; Luzern and Berne, Switzerland; and Antwerp, Belgium
Objectives Our purpose was to perform a systematic review and meta-analysis of randomized trials comparing percutane-
ous coronary intervention (PCI) of the infarct-related artery (IRA) with medical therapy in patients randomized
12 h after acute myocardial infarction (AMI).
Background There is ongoing uncertainty about the risk–benefit ratio of late PCI in stable patients with AMI.
Methods PubMed, CENTRAL, and other databases were searched (July 2007). Studies were included if they compared PCI
with medical management and randomized patients 12 h and up to 60 days after AMI, and were excluded if
patients were hemodynamically unstable. Odds ratios (ORs) were pooled for dichotomous outcomes, with all-
cause mortality as the primary end point. Left cardiac remodeling parameters were also pooled with generic
inverse-variance weighting.
Results We retrieved 10 studies that enrolled 3,560 patients, with median time from AMI to randomization of 12 days
(range 1 to 26 days), and follow-up of 2.8 years (42 days to 10 years). Randomization allocated 1,779 subjects
to PCI and 1,781 to medical treatment. There were 112 (6.3%) and 149 (8.4%) deaths in the 2 groups, respec-
tively, yielding significantly improved survival in the PCI group (OR 0.49 [95% confidence interval (CI) 0.26 to
0.94], p  0.030). These benefits were associated with similarly favorable effects on cardiac remodeling, such
as improved left ventricular ejection fraction in the PCI group (4.4% change [95% CI 1.1 to 7.6], p  0.009).
Conclusions Percutaneous coronary intervention of the IRA performed late (12 h to 60 days) after AMI is associated with sig-
nificant improvements in cardiac function and survival. (J Am Coll Cardiol 2008;51:956–64) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.062i
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che primary therapeutic goal in acute myocardial infarction
AMI) is to achieve early myocardial reperfusion (1). Cur-
ent practice guidelines emphasize the importance of
chieving reperfusion of the infarct-related artery (IRA) as
arly as possible (1). The reperfusion paradigm postulates
ndeed that early reperfusion (12 h) results in salvage of
yocardium at risk with preservation of both regional and
lobal left ventricular function, with ensuing improvements
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or drug-eluting stents and has received various research and/or teaching grants, 2n long-term survival (1–3). The benefit of late (12 h)
eperfusion is, however, controversial. Observational and
See page 965
xperimental data suggest that achieving reperfusion of the
RA may confer benefits that are necrosis-independent and
artially time-independent (2–4). Revascularization of the
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March 4, 2008:956–64 Late PCI After AMI: A Meta-AnalysisRA, therefore, is thought to potentially prevent unfavorable
ost-infarction remodeling and long-term unfavorable out-
omes (1–4). Smaller randomized controlled trials (RCTs)
ave shown mostly nonsignificant or contradictory results,
nd 2 recently published larger trials produced contradictory
esults (5,6).
The aim of our study was to perform a systematic review
nd meta-analysis of all RCTs comparing late percutaneous
oronary intervention (PCI) of the IRA to conservative
ptimal medical management only in the setting of stable
atients late (12 h) in the course of AMI.
ethods
earching. Three trained investigators (A.A., G.B.Z.,
.A.) independently searched PubMed, CENTRAL,
RCT, BioMedCentral, Cardiosource, clinicaltrials.gov,
nd ISI Web of Science using highly sensitive and specific
trategies (7). Search keywords are available in the Appen-
ix. Searches were updated to July 2007. Proceedings from
he 3 major cardiology meetings for the past 3 years were
lso searched. Finally, international experts were queried for
dditional trials.
election. Citations initially selected by systematic search
ere first retrieved as a title and/or abstract and preliminar-
ly screened. Potentially relevant reports were then retrieved
s complete manuscripts and assessed for compliance to
nclusion and exclusion criteria.
Inclusion criteria were: 1) randomized allocation; 2) com-
arison of late PCI versus conservative medical management;
) hemodynamic stability of patients; and 4) angioplasty
erformed late (12 h after onset of symptoms) in the course
f AMI.
Exclusion criteria included: 1) enrollment of patients with
emodynamic or clinical instability (e.g., cardiogenic
hock), or other indications to urgent catheterization; 2)
uplicate publication; 3) enrollment of patients randomized
o PCI within 12 h of symptom onset; or 4) ongoing studies.
alidity assessment. Study quality was evaluated according
o the established methods of the Cochrane Collaboration.
pecifically, we separately estimated the risk of selection,
erformance, detection, attrition bias, and allocation
oncealment.
tudy characteristics. The clinical outcomes of interest
ere defined as death, myocardial infarction, repeat revas-
ularization, or rehospitalization for angina or heart failure
HF) at longest follow-up available, while the impact on
ost-infarction remodeling was assessed by means of
hanges in left ventricular ejection fraction (LVEF), left
entricular end-systolic volume index (LVESVI), and left
entricular end-diastolic volume index (LVEDVI). Mea-
urements were directly abstracted when reported. Oth-
rwise, primary authors were repeatedly contacted to
btain the precise data. Eventually, in case of no or
ncomplete data, these were imputed using means and (tandard deviations from baseline
nd follow-up data according to
n unbiased algorithm (7).
All-cause mortality was consid-
red the primary end point. Sec-
ndary end points were: 1) death
r nonfatal AMI; 2) death, nonfa-
al AMI, or rehospitalization for
ngina or symptoms of heart fail-
re; 3) nonfatal AMI; and 4)
hanges in LVEF, LVESVI, and
VEDVI.
tatistical methods. Statistical
nalysis was performed using the
eview Manager 4.2.4 freeware
ackage (Plone Foundation,
ouston, Texas). Dichotomous
ariables are reported as propor-
ions (percentages), continuous
ariables as mean (standard devi-
tion) or median (range). I2 was
alculated as a measure of statistical heterogeneity, with I2
alues of 25%, 50%, and 75% representing mild, moderate,
nd severe inconsistency, respectively. Binary outcomes
rom individual studies were combined with the
erSimonian-Laird random-effect model, leading to the
omputation of odds ratios (ORs) with 95% confidence
nterval (CI). Continuous variables were pooled using a
andom-effect inverse-variance weighting method. The
umber needed to treat was computed using random-effect
isk differences (RDs).
In order to assess the sensitivity of the results, several
ubgroup analyses were performed. Specifically, we performed
nalyses for the primary end point according to a fixed-effect
ethod, computing relative risks (RRs) and RDs. In addition,
funnel plot of treatment effect versus study precision was
reated for the primary outcome, and the risk of small study
ias was appraised with the Peters’ test.
Finally, we performed meta-regression using inverse-
ariance-weighting (which weighs each study on the basis of
ts precision) to appraise the impact on death and changes in
VEF of time to PCI in the intervention group, follow-up
ength, total IRA occlusion as an inclusion criterion, and
vidence of ischemia as an exclusion criterion.
Reported values were 2-tailed, and results were consid-
red statistically significant at the 0.05 level. Unadjusted p
alues are reported throughout.
esults
earch results and study selection. Overall, the search
ermitted the retrieval of 4,432 citations. We identified 20
ligible citations, which were assessed for compliance to the
nclusion and exclusion criteria. We further excluded 10
tudies: 6 because enrollment was allowed earlier than 12 h
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CI  confidence interval
IRA  infarct-related artery
LVEF  left ventricular
ejection fraction
LVEDVI  left ventricular
end-diastolic volume index
LVESVI  left ventricular
end-systolic volume index
OR  odds ratio
PCI  percutaneous
coronary intervention
RCT  randomized
controlled trial
RD  risk difference
RR  relative risk8–13), 1 because it was a nonrandomized retrospective
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Late PCI After AMI: A Meta-Analysis March 4, 2008:956–64nalysis (14), and 2 because the randomization process was
imited to angiography and not specifically to intervention
15,16). We also excluded the TOSCA (Total Occlusion
tudy of Canada)-2 study (17) for the clinical outcome data
s it represented duplicate data from the OAT (Occluded
rtery Trial) study (5), but included the functional data for
he cardiac remodeling analysis. Ultimately, 10 published
tudies were selected (5,6,18–25) (Fig. 1).
Baseline and follow-up LVEF data were available in 7 of
he 10 studies (6,17,19,20,23,24), while no data were
vailable from the OAT study (5) and ALKK (Arbeitsge-
einschaft Leitende Kardiologische Krankenhausärzte)
tudy (21). Exclusion of the data deriving from the TOAT
The Occluded Artery Trial) study (25) for the cardiac
unction and remodeling analysis deserves specific discus-
ion: patients enrolled in the TOAT, indeed, underwent a
rst assessment of cardiac function as late as 6 weeks after
MI and a second assessment at 12 months; thus, true
aseline values were not available, even after contacting the
rimary investigator of the study.
All studies reported blinding of physicians participating
n the study to randomization with regard to LVEF
ssessment except 1 study in which blinding was not
pecifically reported (20). Baseline and follow-up LVESVI
nd LVEDVI were available in only 4 studies (6,17,20,24).
aseline characteristics. The 10 studies included in the
nal analysis randomized 3,560 patients: 1,779 randomized
o PCI and 1,781 to medical therapy only (Tables 1 and 2).
even studies were multicenter trials (5,6,18,19,21–23); the
emaining were single-center trials (20,23,24). The mean
ge was 59 years. On average, men accounted for 77% of
ubjects. The average of median times from AMI to
ntervention was 12 days (range 1 to 26 days), with the
RAVE-2 (Beyond 12 Hours Reperfusion Alternative
valuation Trial) study (18) being the only study including
nly patients as early as 12 h (up to 48 h) after symptom
nset, and the ALKK study (21) enrolling patients no
ooner than 8 days after AMI. Angiographic documentation
f total IRA occlusion was required as an inclusion criterion
n 5 studies (5,19,20,24,25). Of the remaining studies, 3
equired either total IRA occlusion or significant stenosis
6,21,22), while 2 studies did not define degree of IRA
tenosis as inclusion criteria, but did require definitive
vidence of AMI (18,23). Follow-up duration ranged from
2 days (18) to 10.2 years (6) (average for the median
ollow-up was 2.8 years). The average baseline LVEF was
9%. Demonstration of ischemia was necessary in all pa-
ients in 2 studies (6,18), moderate-to-severe ischemia was
n exclusion criterion in 6 studies (5,19,21,23,25), whereas
he remaining 2 had no specific indications regarding
schemia (22,24). Angiographic PCI success ranged from
2% (23) to 100% (20) (average of 88%). Intracoronary
tents were variably used (range 0% to 100%) and glyco-
rotein IIb/IIIa inhibitors were not routinely used in all but
study (5). The medical regimen varied across the differenttudies and was incompletely reported in many (Table 3). tuantitative data synthesis: clinical outcome. Consider-
ng the primary end point, late PCI for the IRA was
ssociated with a significantly better long-term survival
ersus medical therapy alone (OR for death 0.49 [95% CI
.26 to 0.94], p  0.030, I2  59%) (Fig. 1A). There were
12 deaths in the intervention arm (6.3%) versus 149 deaths
n medical therapy alone arm (8.4%), yielding a number
eed to treat of 28 (95% CI 15 to 200). Indeed, all but 2
tudies showed an OR for death favoring intervention
5,13). Similar results were obtained with random-effect
stimates of RR (RR  0.52 [95% CI 0.29 to 0.95], p 
.028, I2  57%) or RD (RD  4.3% [7.1%; 0.2%],
 0.032, I2  65%).
When compared with medical therapy alone, late inter-
ention was also associated with concordant, albeit nonsig-
ificant, reductions in the composite end points of death or
MI (OR  0.70 [95% CI 0.40 to 1.23], p  0.22, I2 
0%) (Fig. 1B), and death, recurrent AMI, or rehospital-
zation for angina/heart failure (OR 0.66 [95% CI 0.40 to
.11], p  0.12, I2  58%) (Fig. 1C). Recurrent AMI
ccurred with equal frequency in both groups (OR  0.86
95% CI 0.38 to 1.95], p  0.72, I2  74%) (Fig. 1D).
uantitative data synthesis: cardiac function and remod-
ling. Late PCI was associated with a significantly greater
mprovement in LVEF over time versus medical therapy
lone, with an LVEF change of 4.4% (95% CI 1.1 to 7.6,
 0.009, I2  95%) (Fig. 2). With regard to changes in
VESVI and LVEDVI, only 4 studies presented both
aseline and follow-up data. Nonetheless, the difference in
VEDVI changes between the PCI group and control
roup was 7.0 ml/m2 (95% CI 12.18 to 1.81, p 
.008, I2  89%), significantly in favor of PCI (Fig. 2).
imilarly, the difference in changes in LVESVI between the
CI group and control group was 7.5 ml/m2 (95% CI
12.61 to2.47, p 0.004, I2 89%) also in favor of PCI
Fig. 2).
dditional analyses. Sensitivity analyses for the primary
nd point showed results similar in direction and statistical
ignificance for computations performed using a fixed-effect
odel (OR for death 0.74 [95% CI 0.57 to 0.95], p 
.020, I2  64%), RRs (RR 0.52 [95% CI 0.29 to 0.95], p
0.030, I2  57%), or RDs (RD 0.036 [95% CI 0.068
o0.005], p 0.030, I2 65%). Thus, these data support
ur overall findings, despite the evident extent of clinical
nd statistical heterogeneity. Indeed, point estimates and
5% CIs for ORs remained all 1.0 when sequentially
xcluding 1 of 7 studies (5,18–20,22,23,25), while point
stimates were 1.0 but upper limits of 95% CI were 1.0
hen sequentially excluding ALKK (21), Horie et al. (24),
r SWISSI II (Swiss Interventional Study on Silent Isch-
mia Type II) (6) studies. Peters’ test did not disclose the
resence of small study bias (p  0.90), as was also
emonstrated by the funnel plot (Fig. 3).
Meta-regression analysis disclosed significant interactions
etween several variables of interest and outcome; however,
hese results should be viewed as hypothesis-generating
959JACC Vol. 51, No. 9, 2008 Abbate et al.
March 4, 2008:956–64 Late PCI After AMI: A Meta-AnalysisFigure 1 Individual and Pooled Risks of Adverse Outcomes
Forest plots showing individual and pooled risks of death (A), death, and nonfatal recurrent myocardial infarction (B), death, nonfatal recurrent myocardial infarction, or
rehospitalization for angina/heart failure (C), and nonfatal recurrent myocardial infarction (D) comparing late percutaneous coronary intervention (PCI) versus best medi-
cal therapy (Rx) only for infarct-related artery occlusion late (12 h) in the course of acute myocardial infarction. ALKK  Arbeitsgemeinschaft Leitende Kardiologische
Krankenhausärzte; BRAVE-2  Beyond 12 Hours Reperfusion Alternative Evaluation Trial; CI  confidence interval; DEPOCI  Randomized Trial of Occluded Artery Angio-
plasty After Acute Myocardial Infarction; OAT  Occluded Artery Trial; OR  odds ratio; SWISSI II  Swiss Interventional Study on Silent Ischemia Type II; TOAT  The
Occluded Artery Trial; TOMIIS  Total Occlusion Post-Myocardial Infarction Intervention Study; TOPS  Treatment of Post-thrombolytic Stenoses.
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Late PCI After AMI: A Meta-Analysis March 4, 2008:956–64nly, and lack of statistical significance should not be
nterpreted as lack of effect, given the well-known limita-
ions in statistical power of meta-regression. No significant
nteraction between time to PCI and effect was noted.
ength of follow-up showed conversely a significant inter-
ction with changes in LVEF (p  0.001, Beta 0.09) (Fig.
) and a nonsignificant interaction with incidence of death
p  0.072) suggesting that the longer the follow-up the
reater the benefits observed with PCI. Studies that en-
olled also patients with subtotal IRA occlusion showed a
reater benefit from PCI in terms of reduction of mortality
p  0.015), but not in terms of LVEF (p  0.13). Trials
ncluding patients with inducible ischemia or that did not
onsider evidence of ischemia as an exclusion criterion
howed a significantly greater benefit of PCI on LVEF (p 
.027) and a nonsignificantly favorable impact on survival
haracteristics of the 10 Included Studies
Table 1 Characteristics of the 10 Included Studies
Study (Ref. #) Year
No. of
Patients Clinical Scenario (and Time F
ALKK study (21) 2003 300 STEMI (8–42 days after pain onse
BRAVE-2 study (18) 2005 365 STEMI (12–48 h after pain onset)
DECOPI study (19) 2004 212 Q-wave AMI (48 h after pain)
Horie et al. (24) 1998 83 STEMI (24 h from pain)
OAT study (5)
(TOSCA-2 [17])
2006 2,166 AMI (3–28 days after pain onset)
Silva et al. (20) 2005 36 Anterior STEMI (12 h–14 days afte
SWISSI II study (6) 2007 201 AMI (3–58 days) and silent ischem
TOAT study (25) 2002 66 Anterior STEMI, LV dysfunction
TOPS study (22) 1992 87 STEMI (4 days after pain), negat
TOMIIS study (23) 1994 44 STEMI (5–42 days), LV dysfunction
ollow-up represents median value in the study; when multiple follow-up periods were completed
ALKK  Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte; AMI  acute myo
andomized Trial of Occluded Artery Angioplasty After Acute Myocardial Infarction; HF  heart fa
revascularization; STEMI  ST-segment elevation myocardial infarction; SWISSI II  Swiss Inte
ost-Myocardial Infarction Intervention Study; TOPS Treatment of Post-thrombolytic Stenoses; TO
dditional Clinical Characteristics and Details of the Included Stud
Table 2 Additional Clinical Characteristics and Details of the In
Study (Ref. #)
Totally Occluded
IRA at Time of
Randomization as
a Requirement
Angiographic
Success
(Final TIMI
Flow Grade 3
After PCI)
Routine or
Provisional
Use of Stents
R
P
In
ALKK study (21) No 86% Yes (17%) N
BRAVE-2 study (18) No 92% Yes (50%) Y
DECOPI study (19) Yes 82% Yes (80.4%) Y
Horie et al. (24) Yes 86% No N
OAT study (5)
(TOSCA-2 [17])
Yes 85% Yes (91%) Y
Silva et al. (20) Yes 100% Yes (100%) Y
SWISSI II study (6) No 95% No N
TOAT study (25) Yes 94% 67% Y
TOPS study (22) Yes 72% No N
TOMIIS study (23) No 90% No NP  glycoprotein; IRA  infarct-related artery; n/a  not available; TIMI  Thrombolysis In Myocardialp  0.061) versus those trials that excluded patients with
oderate-to-severe ischemia. No interaction between med-
cations given at discharge and benefits from PCI was found
all p  0.10).
Table 4 shows design features for the appraisal of the
nternal validity of included studies. No association between
esign features and effects was observed.
iscussion
his systematic review is based on the statistical pooling of
0 RCTs that enrolled in total more than 3,500 patients
omparing PCI of the IRA with conservative medical
anagement in patients presenting more than 12 h after an
MI. Notwithstanding the limitations inherent to the
MI)
Time to PCI
(days)
Follow-Up
(months) Primary Outcome
23 56 Death/AMI/revasc/hospitalization
1 3 Infarct size (3 months)
5 35 Cardiac death/AMI/VTach-VFib
8 60 LV ejection fraction (6 months)
8 34 Death/AMI/hospitalization for HF
) 8 6 LV end-diastolic volume (6 months)
32 121 Death/AMI/revascularization
26 12 LV size and function
ess test 7 12 LV ejection fraction (6 months)
11 4 LV ejection fraction (4 months)
gest follow-up period was used.
infarction; BRAVE-2  Beyond 12 Hours Reperfusion Alternative Evaluation Trial; DEPOCI 
 left ventricle; OAT  Occluded Artery Trial; PCI  percutaneous coronary intervention; revasc
al Study on Silent Ischemia Type II; TOAT  The Occluded Artery Trial; TOMIIS  Total Occlusion
 Total Occlusion Study of Canada; VFib ventricular fibrillation; VTach ventricular tachycardia.
ed Studies
e or
onal
GP
Ia
rs in
oup
Routine or
Provisional Use of
Clopidogrel or
Ticlopidine
Crossover From
Control Arm to
Intervention Arm
Midterm
Follow-Up
Long-Term
Follow-Up
No Yes (13%) n/a 56 months
) Yes (n/a) Yes (9%) 90 days n/a
) Yes (if stent placed,
30 days)
Yes (9%) n/a 35 months
Not stated No 6 months 60 months
%) Yes (PCI 92.8%,
control group
30.6%)
Yes (8%) 12 months 35 months
%) Yes (all PCI patients
for 30 days)
No 6 months n/a
No Yes (31%) 48 months 121 months
) Yes (all PCI patients
for 2 weeks)
Yes (9%) 12 months n/a
Not stated No 4 months n/a
No Yes (11%) 12 months n/arom A
t)
r pain
ia
ive str
, the lon
cardial
ilure; LVies
clud
outin
rovisi
Use of
IIb/II
hibito
PCI Gr
o
es (n/a
es (9%
o
es (81
es (22
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o
oInfarction; other abbreviations as in Table 1.
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March 4, 2008:956–64 Late PCI After AMI: A Meta-Analysisrimary studies, this meta-analysis includes the largest
ohort to date and shows a statistically significant survival
nd remodeling advantage in favor of PCI of the IRA late
fter AMI.
ignificant findings and clinical implications. The find-
ngs of a beneficial effect of late PCI proposes that
Figure 2 Individual and Pooled Group Differences in Changes in
Forest plot showing individual and pooled changes in left ventricular ejection fracti
late PCI versus best medical therapy only for infarct-related artery occlusion late (
ventricular ejection fraction favoring PCI. (B and C) Show a significant greater decr
ume index in the PCI, showing a more favorable remodeling pattern with PCI. TOSC
edication Use in Control and PCI Groups for Each Study
Table 3 Medication Use in Control and PCI Groups for Each St
Study (Ref. #)
ACEI or ARB Beta-Blo
Control Group PCI Control Group
ALKK study (21) n/a 61%
BRAVE-2 study (18) n/a n/a
DECOPI study (19) 57%* 81%
Horie et al. (24) 23% 11% 28%
OAT study (5)
(TOSCA-2 [17])
80% 80% 86%
Silva et al. (20) 100% 100% 83%
SWISSI II study (6) 47% 34% 84%
TOAT study (25) 100% 100% 82%
TOPS study (22) 82% 62% 94%
TOMIIS study (23) n/a 37%
Values stated apply to entire cohort with no breakdown of figures according to arm of study; text sta
o protocol, but actual rate not given; value in table represents antiplatelet agent at baseline not
ACEI  angiotensin converting enzyme inhibitor; ARB  angiotensin receptor blocker; ASA  aevascularization of the IRA by means of PCI occurring
ate and beyond the window of myocardial salvage can be
avorable in terms of post-AMI cardiac remodeling and
ll-cause mortality. The clinical implications of such
ndings are potentially very significant. The number of
atients treated within 12 h of the onset of symptoms is
iac Function and Remodeling
d-diastolic volume index, and end-systolic volume index at follow-up comparing
in the course of acute myocardial infarction. (A) Shows a 4% change in left
in left ventricular end-diastolic volume index and left ventricular end-systolic vol-
Total Occlusion Study of Canada; other abbreviations as in Figure 1.
Statins
Antiplatelet (ASA 
Clopidogrel or Ticlopidine)
PCI Control Group PCI Control Group PCI
68% n/a n/a
n/a 100% 100%
82%* 83%*
27% n/a 47%† 64%†
89% 80% 82% 94% 97%
100% 25% 39% 100% 100%
39% 61% 73% 100%†
84% n/a n/a
79% n/a 100% 100%
37% n/a n/a
t values were similar or the same in each group; †all were given aspirin at randomization according
defined in text.
licylic acid; n/a  not available; other abbreviatons as in Table 1.Card
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Late PCI After AMI: A Meta-Analysis March 4, 2008:956–64till disappointing, with 8.5% to 40% of patients present-
ng beyond 12 h (18).
athophysiological mechanisms. The “open artery hy-
othesis” speculates that restoration of anterograde blood
ow to the peri-infarct area is beneficial to the myocardium
ven late and beyond the time limit set for salvage from
yocardial necrosis (2–4). A detailed discussion of the
roposed mechanism by which late reperfusion is associated
ith late improvement in left ventricular function is beyond
he scope of this review. Salvage of myocardium at risk
“hibernating” myocardium) from death due to apoptosis
ay be a plausible explanation (4,26,27). Ischemia can
ndeed induce apoptosis in cardiomyocytes and even late
eperfusion may favorably affect the apoptotic cascade
4,26,27). Moreover, ischemia itself stimulates formation of
ollateral circulation, which in the setting of AMI can serve
o preserve some degree of retrograde perfusion, potentially
xtending the period of viability of myocardium at risk (28).
iability of stunned myocardium has indeed been demon-
trated weeks after AMI, suggesting that reperfusion of the
RA could interrupt the progression from hibernating
yocardium to necrotic/apoptotic myocardium (29).
It is worth mentioning that while the TOAT study (25)
emonstrated a trend towards adverse remodeling in the
CI arm, a substudy on 26 patients who underwent dobut-
mine stress cardiac magnetic resonance imaging to assess
yocardial viability demonstrated that PCI had a beneficial
ffect on remodeling in patients with demonstrable myocar-
ial viability (30).
According to these premises, late PCI of the IRA was
ssociated with preservation of left ventricular function and
ore favorable cardiac remodeling in our data. These data
uggest that late PCI may prevent death by preventing the
ccurrence of ischemic cardiomyopathy. The lack of differ-
nce in terms of recurrent AMI suggests that prevention of
ecurrent AMI is not necessarily the means by which late
Figure 3 Lack of Small Study Bias
Funnel plot of study effect (odds ratio) versus precision (standard error of log-
transformed odds ratio) suggests the lack of small study bias (p  0.896 at
Peters’ test).CI prevents death.alidity and potential limitations of the meta-analysis. As
ith any meta-analysis, there are inherent difficulties in
sing data from multiple studies of a similar nature to derive
onclusions about an overall effect of a particular interven-
ion. Substantial statistical inconsistency was detected in
his study, which highlights the presence of significant
ifferences between the included studies, without, however,
uestioning the validity of the statistical analysis performed
sing a random effect pooling. The 2 most recently pub-
ished studies in this analysis (OAT [5] and SWISSI II [6])
ave important differences in study design and length of
ollow-up and, not surprisingly, show conflicting results;
WISSI-II (6) randomized only patients with proven silent
schemia on stress testing, whereas the OAT (5) excluded
hose patients with post-infarction angina and/or moderate-
o-severe ischemia. Our analysis suggests, indeed, that
tudies that did not exclude patients with ischemia showed
greater benefit from late PCI. However, one-third to
wo-thirds of patients have residual symptomatic or silent
schemia after AMI (31,32), and there is some debate on
hether the OAT study is representative of real life treat-
ent scenarios (33). Recruitment in the OAT study was
ndeed difficult and interrupted early: only 2 patients per
ear per center were enrolled on average representing a very
mall minority of patients (5,33). In addition, length of
ollow-up was dramatically different between these 2 stud-
es, with the SWISSI II following patients for a median of
0.2 years, while less than one-half of the patients in the
AT study had a follow-up that reached 3 years. Moreover,
urvival curves in the OAT study at 4 years were constructed
Figure 4 Correlation Between Length of
Follow-Up and Changes in Cardiac Function
Meta-regression represents interaction between lengths of follow-up and
observed changes in left ventricular ejection fraction (LVEF), showing greater
benefits of late percutaneous coronary intervention with increasing duration of
follow-up (p  0.001).
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March 4, 2008:956–64 Late PCI After AMI: A Meta-Analysissing estimates, which may have overestimated event rates
n the intervention arm due to early attrition of procedural-
elated events and underestimated late effects of interven-
ion (i.e., prevention of heart failure), which may become
pparent only several years later (5,33). Of note, only 3
ndividual studies have shown a significant improvement in
eath or death and heart failure (ALKK [21], Horie et al.
24], and SWISSI II [6]), and all 3 studies had a median
ollow-up of 4 years.
Moreover, many studies, including the OAT (5), re-
uired that all patients had demonstrated total occlusion of
he IRA in order to qualify for randomization, whereas
thers, including SWISSI II (6) and ALKK (21), required
he presence of a hemodynamically significant IRA stenosis
or inclusion, thus including also patients with subtotally
ccluded IRA. Variable severity of the IRA lesion could
ertainly affect the size of the benefit observed from PCI,
ith greater benefits for subtotal occlusions; although the
reat majority of patients included in the studies (84%) had
 totally occluded IRA, our analysis suggests greater benefits
hen patients with subtotal IRA occlusions were also
ncluded.
mplications for further research. The available evidence
rom individual trials examining the effects of late PCI has
ot been able to establish a clear benefit. The data from our
eta-analysis suggests that a survival benefit may indeed
xist. Patient selection and adequate length of follow-up
ay prove to be essential in determining who is likely to
enefit the most from late PCI. Patients symptomatic for
ngina or heart failure and those with residual ischemia or
ocumented viability are more likely to benefit from late
CI at a long-term follow up. Patients with uncomplicated
MI, especially if with reduced life expectancy, however,
ay not benefit from routine PCI. Even in the absence of
ignificant effects on hard end points, the OAT study
howed that patients treated with PCI were significantly less
ikely to be symptomatic for angina at 4, 12, and 24 months
5). The OAT study (5), however, also showed a potential
or harm associated with late PCI, in terms of an increased
ate of recurrent AMI. This has not been confirmed in our
eta-analysis and did not affect survival in the OAT cohort,
ut it illustrates the inherent limitations and potential
ong-term complications of PCI as a means of achieving
ustained reperfusion, and highlights the need for further
efinement in PCI technology and adjunctive medical ther-
py to improve longevity of IRA patency.
onclusions
his review presents a meta-analysis of data from 10 RCTs
n which patients treated late (12 h) during the course of
MI were randomized to PCI of the IRA versus conser-
ative management and shows a survival advantage in
erforming PCI late in the course of an AMI, associated
ith a more favorable post-infarction cardiac remodeling
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PPENDIX
earch Strategy
he investigators independently searched PubMed, CEN-
RAL, mRCT, BioMedCentral, Cardiosource, clinicaltri-
ls.gov, and ISI Web of Science using highly sensitive and
pecific strategies (7). Search keywords included ‘random-
zed,’ ‘percutaneous coronary intervention,’ ‘PCI,’ ‘stent,’
angioplasty,’ ‘revasc*,’ ‘recanaliz*,’ ‘acute myocardial infarc-
ion,’ ‘AMI,’ ‘infarct*,’ ‘occlusion,’ and ‘occlu*’ (where *
enotes a wildcard). Searches were updated to July 2007. No
anguage restriction was used. Proceedings from the annual
merican Heart Association, American College of Cardi-
logy, and European Society of Cardiology meetings for the
ast 3 years were also manually searched. Finally, interna-
ional experts were queried for additional trials.
